Pivotal patents have been granted to Netherlands-based global life sciences and materials sciences companyDSM in Europe, Japan andCanada for its innovative yeast-based succinic acid productiontechnology, with exclusive rights awarded to Reverdia, a joint venture between DSM and Roquette Frères, the global starch and starch-derivatives company.
The new patents cover key technology, which is essential to make economically-viable and sustainable biobased succinic acid.
Reverdia President Marcel Lubben said, “Reverdia has developed and commercialised best-in-class, sustainable yeast-based biosuccinic acid technology, proven at commercial scale in our plant located within the Roquette Italian biorefinery. These latest patents are key to making bio-succinic acid commercially-viable.”
The technology under license, will be offered in line with the licensing strategy announced in October 2014, according to Lubben. “Reverdia will continue to strengthen its patent portfolio to ensure the best and most defensible technology offering for its licensees,” he added.
Patents granted are:
1/ CA 2730595 entitled low PH dicarboxylic acid production was granted in Canada on 16 December 2014.
2/ EP2220232 entitled succinic acid production in a eukaryotic cell was granted in Europe on 3 September 2014.
3/ JP5641938 entitled succinic acid production in a eukaryotic cell was granted in Japan on 7 November 2014.
4/ CA 2704654 entitled succinic acid production in a eukaryotic cell was granted in Canada on 10 February 2015.
(PRA)
